FindTrial
Sign In

Post marketing study of Herceptin in patients with HER2-overexpressing metastatic breast cancer

Post marketing study of Herceptin in patients with HER2-overexpressing metastatic breast cancer

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220021
Enrollment
Unknown
Registered
2005-09-01
Start date
2005-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HER2-overexpressing metastatic breast cancer

Interventions

investigational material(s) Generic name etc : Trastuzumab (Herceptin) INN of investigational material : Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investiga

Sponsors

Chugai Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Female patients and over 20 years with metastatic breast cancer, who do not have any chemotherapeutics to metastatic breast cancer. Whenever possible, the disease will be assessed for HER2 status. Patients who have HER2 overexpression or amplification in their disease(3+by immunohistochemistry or FISH positive),will be allowed to enter this study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
1) Time to progression (TTP) on Herceptin alone (Cohort A) versus combination of Herceptin and Taxotere (Cohort B) 2) Overall survival(OS)—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026